Transplanted kidney loss during colorectal cancer chemotherapy: A case report

Table 1 Timeline of diagnostic procedures and treatment

Date	Procedure
1994	Diagnosis of glomerular nephritis (kidney biopsy)
1994	Therapy with glucocorticoids and cyclophosphamide
2004	Initiation of hemodialysis therapy
2005	Kidney transplantation
October 2020	Recurrent abdominal pain
January 26, 2021	Right hemicolectomy
February 2021	Initiation of adjuvant chemotherapy (FOLFOX-4)
February 25, 2021	Abdominal laceration abscess surgery
March 17 to 19, 2021	1st FOLFOX-4
April 1, 2021	2nd FOLFOX-4
April 19, 2021	Postponement of chemotherapy
May 5, 2021	Postponement of chemotherapy
May 14, 2021	Adjuvant chemotherapy termination
June 1, 2021	Kidney graft biopsy
June 17, 2021	First CT of the abdomen and pelvis
September 30, 2021	Second CT of the abdomen and pelvis
October 28, 2021	Surgical creation of an arteriovenous shunt
October 29, 2021	PET-CT
December 8, 2021	Initiation of hemodialysis therapy
December 21, 2021	Initiation of palliative chemotherapy (FOLFOX-4)

CT: Computed tomography; PET–CT: Positron emission tomography–computed tomography.

Table 2 Clinical characteristics of kidney transplant patients treated with adjuvant (n = 7) and palliative chemotherapy (n = 5) for colorectal cancer

Refs	Patients	Sex	Age at diagnosis, yr	Clinical stage	Chemotherapy	Cycles	Graft loss	ADR	Response	DFS/PFS (mo)	OS (mo)
Kim et al[5]	5 of 171	6 W, 11 M	54 ± 7	Stage 0 (n = 2)			Yes, 2 (within 1 yr)			25.1 ± 9.2
				Stage I (n = 5)
				Stage II (n = 3)	FU-LV (n = 1)	12		NS			NA
				Stage III (n = 3)	Capecitabine (n = 2)	12		NS			25
				Stage IV (n = 4)	Capecitabine (n = 1); FU-LV (n = 1)	812		NS			10
Fang[20]	1	M	36	Stage II (pT3N0M0)	FOLFOX	3	No	NS	PD	0	NA
Liu et al[24]	2	M	44	Stage II (pT3N0M0)	Capecitabine	8	No	NA	SD	NA	Alive after 21
		M	54	Stage II (pT3N0M0)	Capecitabine	8	No	NA	SD	NA	Alive after 8
Xia et al[25]	1	M	51	Stage III B (pT3N1M0)	FOLFOX	8	No	NS	PR	NA	NA
Liu et al[24]	1	M	68	Stage III (pT4N1M0)	Capecitabine (after progression)	3	No	NS	PR	2	4-5 for CTH
Müsri et al[26]	1	M	64	Stage IV	FOLFIRI + bevacizumab	5	NS	Proteinuria	PR (regression of liver metastasis)	NA	NA
								Deterioration of kidney function
Bellyei et al[19]	1	M	66	Stage IV	FOLFIRI + cetuximab	1	No	Blood sugar level fluctuation	NA	NA	NA
								Diarrhea
								Hypomagnesemia
					FOLFIRI + panitumumab	3	No	Weight loss	PR(paraaortic lymph node regression)	NA	NA
								Diarrhea
								Hypomagnesemia
					SBRT + panitumumab	16	No	Skin rash	CR	NA	NA-stroke
								Hypomagnesemia

¹Characteristics and outcome data for 17 patients cohort, including 5 patients that received CTH.

M: Man; W: Women; ADR: Adverse drug reaction; DSF: Disease-free survival; PFS: Progression-free survival, OS: Overall survival; NS: Not specified; NA: Not available; FU-LV: 5-flurouracil-leucovorin; PD: Progressive disease; SD: Stable disease; PR: Partial Response; SBRT: Stereotactic body irradiation; CR: Complete response.